977: Circulating free DNA: a ‘liquid biopsy’ for the early detection of cancer?

2014 ◽  
Vol 50 ◽  
pp. S238
Author(s):  
R.M. Trigg ◽  
S.M. Giblett ◽  
C.A. Pritchard ◽  
J.A. Shaw
Author(s):  
M. Del Re ◽  
V. Conteduca ◽  
S. Crucitta ◽  
G. Gurioli ◽  
C. Casadei ◽  
...  

Abstract Background Androgen receptor (AR) signaling inhibitors represent the standard treatment in metastatic castration resistance prostate cancer (mCRPC) patients. However, some patients display a primary resistance, and several studies investigated the role of the AR as a predictive biomarker of response to treatment. This study is aimed to evaluate the role of AR in liquid biopsy to predict clinical outcome to AR signaling inhibitors in mCRPC patients. Methods Six milliliters of plasma samples were collected before first-line treatment with abiraterone or enzalutamide. Circulating free DNA (cfDNA) and exosome-RNA were isolated for analysis of AR gain and AR splice variant 7 (AR-V7), respectively, by digital droplet PCR. Results Eighty-four mCRPC patients received abiraterone (n = 40) or enzalutamide (n = 44) as first-line therapy. Twelve patients (14.3%) presented AR gain and 30 (35.7%) AR-V7+ at baseline. Median progression-free survival (PFS) and overall survival (OS) were significantly longer in AR-V7− vs AR-V7+ patients (24.3 vs 5.4 months, p < 0.0001; not reached vs 16.2 months, p = 0.0001, respectively). Patients carrying the AR gain had a median PFS of 4.8 vs 24.3 months for AR normal patients (p < 0.0001). Median OS was significantly longer in AR normal vs patients with AR gain (not reached vs 8.17 months, p < 0.0001). A significant correlation between AR-V7 and AR gain was observed (r = 0.28; p = 0.01). The AR gain/AR-V7 combined analysis confirmed a strong predictive effect for biomarkers combination vs patients without any AR aberration (PFS 3.8 vs 28 month, respectively; OS 6.1 vs not reached, respectively; p < 0.0001). Conclusions The present study demonstrates that cfDNA and exosome-RNA are both a reliable source of AR variants and their combined detection in liquid biopsy predicts resistance to AR signaling inhibitors.


2019 ◽  
Vol 25 (1) ◽  
pp. 1-9
Author(s):  
Benjamin Mwesige ◽  
Seung-Gu Yeo ◽  
Byong Chul Yoo

Author(s):  
Sinong Jia ◽  
Li Xie ◽  
Lei Li ◽  
Ying Qian ◽  
Jie Wang ◽  
...  

Oncotarget ◽  
2018 ◽  
Vol 9 (61) ◽  
pp. 31904-31914 ◽  
Author(s):  
Akemi Sato ◽  
Chiho Nakashima ◽  
Tomonori Abe ◽  
Junichi Kato ◽  
Mitsuharu Hirai ◽  
...  

2021 ◽  
Vol 13 (11) ◽  
pp. 1799-1812
Author(s):  
Isabelle Uhe ◽  
Monika Elisabeth Hagen ◽  
Frédéric Ris ◽  
Jeremy Meyer ◽  
Christian Toso ◽  
...  

2018 ◽  
Vol 8 (2) ◽  
pp. 1399-1407
Author(s):  
Sameer Chhetri Aryal ◽  
Gopi Aryal

Cancers of the uterine cervix, breast, lung and stomach are four of the most common cancers in Nepal. Lack of knowledge and awareness about cancer, its risk factors and negligence of the early warning signs play crucial role in raising the incidence of the cancer. Curative therapies are most successful when cancer is diagnosed and treated at an early stage.Organized cancer screening programmes provide screening to target population and use multidisciplinary delivery teams, coordinated clinical oversight committees, and regular review by a multidisciplinary evaluation board. For population-based screening programs, decision- making and governance structures, tasks and procedures need to be defined.In this paper, we review population-based cancer screening programmes of different countries and share recommendations and relevant evidence for screening and early detection of common cancers in Nepal. The evidence-based recommendations provided in this Review are intended to act as a guide for policy makers, clinicians, and public health practitioners who are developing and implementing strategies in cancer control.  We also discuss the role of liquid biopsy in early detection, diagnosis and monitoring of cancers using circulating biomarkers. Despite challenges, time has come to include cell free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), as a parameters for early detection of cancer in the days to come.


Sign in / Sign up

Export Citation Format

Share Document